Compare Crispr Therapeutics AG (CRSP) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Petróleo Brasileiro SA — how do they compare? Crispr Therapeutics AG trades at $50.47 (market cap $4.97B), while Petróleo Brasileiro SA trades at $17.73 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 21.7× Crispr Therapeutics AG's market cap, and Petróleo Brasileiro SA pays a 9.84% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PBR | |
|---|---|---|
Market Cap | $4.97B | $108.05B |
Sector | Health | Technology |
52-Week High | $76.78 | $22.03 |
52-Week Low | $44.34 | $11.54 |
Enterprise Value | $3.32B | $170.59B |
Dividend Yield | — | 9.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
PBR trades at $17.88, up 3.23% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 5.71, net income margin of 21.47%, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments, supporting growth prospects amid positive analyst sentiment.
Outlook remains favorable with a consensus price target of $23.90, representing 33.6% upside potential. Key risks include oil price volatility and execution of new projects. The combination of low valuation, robust cash flow, and strategic expansion provides a compelling case for long-term investors, though market fluctuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
